Program for Assessment of Capecitabine (Xeloda) Plus Docetaxel First-line Therapies in HER2-negative Metastatic Breast Cancer (XEBRA Study)
Phase of Trial: Phase IV
Latest Information Update: 23 Aug 2016
Price : $35 *
At a glance
- Drugs Capecitabine (Primary) ; Docetaxel
- Indications Advanced breast cancer; Male breast cancer
- Focus Therapeutic Use
- Acronyms XEBRA
- Sponsors Roche
- 09 Mar 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 23 Dec 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 15 Dec 2014 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.